Steroid-refractory ulcerative colitis: a critical review of national and international guideline recommendations

Zusammenfassung

Es gibt zahlreiche nationale und internationale Leitlinien zu chronisch entzündlichen Darmerkrankungen, die auf vergleichbarer Evidenz sowie ähnlichen Prozeduren beruhen und daher homogen sein sollten. In dieser kritischen Übersicht wurden die Leitlinienempfehlungen aus Europa (ECCO), Deutschland, Großbritannien, Kanada, den USA und Japan zur Therapie der steroidrefraktären Colitis ulcerosa verglichen. Die meisten Leitlinien unterschieden zwischen moderater/schwerer (ambulanter) und schwerer/fulminanter Colitis in der Klinik. Die Empfehlungen zur ersten Kategorie weisen gravierende Unterschiede auf, während zur Behandlung des stationären Patienten weitgehende Übereinstimmung herrscht. Verschiedene Erklärungen für die Inkonsistenzen werden diskutiert.

Abstract

There is a multitude of national and international guidelines in the IBD sector, all of which are based on similar evidence as well as similar consensus procedures and therefore should be rather homogeneous. This critical review was undertaken to compare the guideline recommendations from Europe (ECCO), Germany, the United Kingdom, Canada, the USA, and Japan in the specific clinical area of how to treat steroid-refractory ulcerative colitis. Most but not all of the guidelines were structured into a part covering moderate/severe outpatient colitis and another section dealing with severe, sometimes fulminant inpatient disease. The recommendations in the first part display major discrepancies whereas there is largely agreement in the inpatient situation. Overall, national and international guidelines lack consistency. Reasons for these discrepancies are discussed.

Schlüsselwörter

Colitis ulcerosa - steriod-refraktär - Leitlinien

Keywords

Ulcerative colitis - steroid-refractory - guidelines

Publikationsverlauf

Eingereicht: 29. Januar 2021

Angenommen nach Revision: 11. April 2021

Artikel online veröffentlicht:
23. Juni 2021

• References

• 1 Graham R, Mancher M, Miller Wolman D. et al. Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice GuidelinesClinical Practice Guidelines We Can Trust. Washington (DC): National Academies Press (US); 2011
• 2 Klag T, Stange EF, Wehkamp J. Management of Crohn’s disease—are guidelines transferred to clinical practice?. United European Gastroenterol J 2015; 3: 371-380
• 3 Guyatt GH, Oxman AD, Kunz R. et al. Going from evidence to recommendations. BMJ 2008; 336: 1049-1051
• 4 Stange EF, Travis SPL, Vermeire S. et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: definitions and diagnosis. J Crohns Colitis 2008; 2: 1-23
• 5 Travis SPL, Stange EF, Lémann M. et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohns Colitis 2008; 2: 24-62
• 6 Harbord M, Eliakim R, Bettenworth D. et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn’s Colitis 2017; 11: 769-784
• 7 Panaccione R, Ghosh S, Middleton S. et al. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.e3
• 8 Sandborn WJ, van Assche G, Reinisch W. et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 257-265.e1–3
• 9 Rutgeerts P, Sandborn WJ, Feagan BG. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476
• 10 Sandborn WJ, Feagan BG, Marano C. et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95; quiz e14–15
• 11 Singh S, Fumery M, Sandborn WJ, Murad MH. Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 162-175
• 12 Sands BE, Peyrin-Biroulet L, Loftus EV. et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med 2019; 381: 1215-1226
• 13 Laharie D, Bourreille A, Branche J. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-1915
• 14 Williams JG, Alam MF, Alrubaiy L. et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. The Lancet Gastroenterol Hepatol 2016; 1: 15-24
• 15 Narula N, Marshall JK, Colombel J-F. et al. Systematic review and meta-analysis: infliximab or cyclosporine as rescue therapy in patients with severe ulcerative colitis refractory to steroids. Am J Gastroenterol 2016; 111: 477-491
• 16 Walch A, Meshkat M, Vogelsang H. et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010; 4: 398-404
• 17 Actis GC, Fadda M, David E, Sapino A. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol 2007; 7: 13
• 18 Schmidt KJ, Herrlinger KR, Emmrich J. et al. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis—experience in 130 patients. Aliment Pharmacol Ther 2013; 37: 129-136
• 19 Kucharzik T, Dignaß A, Siegmund B. Aktualisierung der Colitis ulcerosa Leitlinie 2020. Z Gastroenterol 2020; 58: 1209-1232
• 20 Sandborn WJ, Su C, Sands BE. et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2017; 376: 1723-1736
• 21 Sands BE, Sandborn WJ, Panaccione R. et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2019; 381: 1201-1214
• 22 Bonovas S, Lytras T, Nikolopoulos G. et al. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2018; 47: 454-465
• 23 Pantavou K, Yiallourou AI, Piovani D. et al. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: a systematic overview of meta-analyses. United European Gastroenterol J 2019; 7: 1285-1303
• 24 Laharie D, Bourreille A, Branche J. et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. Gut 2018; 67: 237-243
• 25 Lamb CA, Kennedy NA, Raine T. et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68: S1-106
• 26 Burisch J, Vardi H, Schwartz D. et al. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. The Lancet Gastroenterol Hepatol 2020; 5: 454-464
• 27 Leeds IL, Sundel MH, Gabre-Kidan A. et al. Outcomes for ulcerative colitis with delayed emergency colectomy are worse when controlling for preoperative risk factors. Dis Colon Rectum 2019; 62: 600-607
• 28 Tiu SPT, Hajirawala LN, Leonardi C. et al. Delayed surgery does not increase risk in urgent colectomy for ulcerative colitis. The American Surgeon 2020; 000313482097157
• 29 Narula N, Fine M, Colombel J-F. et al. Systematic review: sequential rescue therapy in severe ulcerative colitis: do the benefits outweigh the risks?. Inflamm Bowel Dis 2015; 21: 1683-1694
• 30 Bitton A, Buie D, Enns R. et al. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012; 107: 179-194
• 31 Bressler B, Marshall JK, Bernstein CN. et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology 2015; 148: 1035-1058.e3
• 32 Chande N, Wang Y, MacDonald JK. et al. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014;
• 33 Wang Y, MacDonald JK, Vandermeer B. et al. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2015;
• 34 Ternant D, Mulleman D, Lauféron F. et al. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis: infliximab in spondylitis. Brit J Clin Pharmacol 2012; 73: 55-65
• 35 Ko CW, Singh S, Feuerstein JD. et al. AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019; 156: 748-764
• 36 Feuerstein JD, Isaacs KL, Schneider Y. et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020; 158: 1450-1461
• 37 Singh S, Allegretti JR, Siddique SM. et al. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020; 158: 1465-1496.e17
• 38 Turner D, Walsh CM, Steinhart AH, Griffiths AM. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-110
• 39 Timmer A, Patton PH, Chande N. et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2016;
• 40 Hu A, Kotze PG, Burgevin A. et al. Combination therapy does not improve rate of clinical or endoscopic remission in patients with inflammatory bowel diseases treated with vedolizumab or ustekinumab. Clin Gastroenterol Hepatol 2020;
• 41 Llaó J, Naves JE, Ruiz-Cerulla A. et al. Intravenous corticosteroids in moderately active ulcerative colitis refractory to oral corticosteroids. J Crohn’s Colitis 2014; 8: 1523-1528
• 42 Matsuoka K, Kobayashi T, Ueno F. et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J Gastroenterol 2018; 53: 305-353
• 43 Zhu M, Xu X, Nie F. et al. The efficacy and safety of selective leukocytapheresis in the treatment of ulcerative colitis: a meta-analysis. Int J Colorectal Dis 2011; 26: 999-1007
• 44 Sakuraba A, Motoya S, Watanabe K. et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009; 104: 2990-2995
• 45 Sandborn WJ, Ghosh S, Panes J. et al. Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis. Gastroenterology 2020; 158: 2139-2149.e14
• 46 Sandborn WJ, Feagan BG, Wolf DC. et al. Ozanimod induction and maintenance treatment for ulcerative colitis. N Engl J Med 2016; 374: 1754-1762
• 47 Sandborn WJ, Ferrante M, Bhandari BR. et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with ulcerative colitis. Gastroenterology 2020; 158: 537-549.e10
• 48 Malheiro R, de Monteiro-Soares M, Hassan C. et al. Methodological quality of guidelines in gastroenterology. Endoscopy 2014; 46: 513-525
• 49 Pocock SJ, Stone GW. The primary outcome is positive—is that good enough?. N Engl J Med 2016; 375: 971-979